Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
| Autor: | Doo Hyun Chung, Do-Youn Oh, Tae-You Kim, Kyung-Hun Lee, Dae Seog Heo, Yung-Jue Bang, Dong Wan Kim, Seock-Ah Im, Sae-Won Han, Pil Gyu Hwang |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Lung Neoplasms Paclitaxel medicine.medical_treatment DNA Mutational Analysis Antineoplastic Agents medicine.disease_cause Deoxycytidine Gefitinib Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Medicine Humans Radiology Nuclear Medicine and imaging Epidermal growth factor receptor Lung cancer Retrospective Studies Mutation Chemotherapy biology business.industry General Medicine Genes erbB-1 medicine.disease Chemotherapy regimen Immunohistochemistry Gemcitabine ErbB Receptors Genes ras Oncology Cancer research biology.protein Quinazolines KRAS business Proto-Oncogene Proteins c-akt medicine.drug |
| Zdroj: | Japanese journal of clinical oncology. 36(6) |
| ISSN: | 0368-2811 |
| Popis: | Background: The association of epidermal growth factor receptor (EGFR) mutations with the response to conventional cytotoxic chemotherapeutic agents in non-small-cell lung cancer patients has not been investigated. We retrospectively analyzed the associations between response to chemotherapy and molecular markers associated with gefitinib responsiveness including EGFR mutations. Methods: EGFR (exons 18, 19 and 21) and K-ras mutations (exon 2) were studied by direct sequencing and p-Erk and p-Akt expressions were studied by immunohistochemistry in archival paraffin embedded tissues. Response rate (RR) and time-to-progression (TTP) of prior chemotherapy by platinum, paclitaxel and gemcitabine were analyzed with respect to the presence of EGFR and K-ras mutations, and p-Erk and p-Akt expressions. Results:Of90patientsinvestigated,75receivedplatinumsand45receivedpaclitaxelasfirst-line chemotherapyagents.TheRRS andTTPS ofplatinum-andpaclitaxel-containingregimenswere not affected by EGFR or K-ras mutations, nor by p-Erk or p-Akt expression. Fifty-seven patients received gemcitabine as first- or second-line chemotherapy. RR was not affected by EGFR or Kras mutations or by p-Akt expression. However, all responders to gemcitabine exhibited (+) p-Erk expression [RR 30.6% for p-Erk (+) versus 0% for p-Erk (� ), P = 0.01]. TTP was not affected by EGFR or K-ras mutations or by p-Erk or p-Akt expression. Conclusions: EGFR mutations did not affect response to conventional chemotherapeutic agents, namely platinums, paclitaxel and gemcitabine. Our results also suggest that it may be undesirable to use gemcitabine in patients with tumors not expressing p-Erk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|